D-Cyclins regulate the cell cycle by acting in a complex with cyclin dependent kinases (CDKs) to promote phosphorylation of the retinoblastoma protein and initiate cellular progression from the G1 to the S phase. Cell cycle deregulation in many cancers often results from altered cyclin D/CDK activity. S14161 is a small molecule inhibitor of cyclins D1-D3 expression that inhibits phosphoinositide 3-kinase activity and arrests cells at the G0/G1 phase in a dose-dependent manner (concentrations tested from 5-10 μM). S14161 induces apoptosis in myeloma and leukemia cell lines (IC50s < 10 μM) but is less toxic to normal hematopoietic cells (IC20 > 25 μM). In a mouse model of leukemia, S14161 delayed tumor growth by up to 90% compared to controls at a dose of 100 mg/kg/day.
S14161 is a small-molecule inhibitor of D-cyclin transactivation that displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway.
D-Cyclins regulate the cell cycle by acting in a complex with cyclin dependent kinases (CDKs) to promote phosphorylation of the retinoblastoma protein and initiate cellular progression from the G1 to the S phase. Cell cycle deregulation in many cancers often results from altered cyclin D/CDK activity. S14161 is a small molecule inhibitor of cyclins D1-D3 expression that inhibits phosphoinositide 3-kinase activity and arrests cells at the G0/G1 phase in a dose-dependent manner (concentrations tested from 5-10 μM). S14161 induces apoptosis in myeloma and leukemia cell lines (IC50s < 10 μM) but is less toxic to normal hematopoietic cells (IC20 > 25 μM). In a mouse model of leukemia, S14161 delayed tumor growth by up to 90% compared to controls at a dose of 100 mg/kg/day.[Cayman Chemical]
[1] XINLIANG MAO. A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway.[J]. Blood, 2011: 1986-1997. DOI:
10.1182/blood-2010-05-284810
